8-K: Silence Therapeutics Q1 2026 Update: Divesiran Trial Progress

Silence Therapeutics plc reported Q1 2026 financial results, highlighting progress in its Phase 2 SANRECO trial for divesiran, with topline results anticipated in August 2026.

Summary

• Silence Therapeutics plc announced its financial results for the first quarter ended March 31, 2026.
• The company is advancing its Phase 2 SANRECO trial for divesiran, a first-in-class siRNA for polycythemia vera (PV), with topline results expected in August 2026.
• The SANRECO Phase 1 study abstract was accepted for poster presentation at the European Hematology Association (EHA) 2026 Annual Congress.
• SLN312 (AZD1705), a Phase 1 siRNA for dyslipidemia, had its abstract accepted for late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress.
• As of March 31, 2026, the company had $70.1 million in cash, cash equivalents, and short-term investments.
• Collaboration revenue from AstraZeneca was $0.4 million for Q1 2026.
• R&D expenses decreased to $9.1 million in Q1 2026 from $20.8 million in Q1 2025, primarily due to the completion of zerlasiran Phase 3 readiness.
• General and administrative expenses were $7.0 million in Q1 2026, down from $7.7 million in Q1 2025.
• The net loss for Q1 2026 was $15.0 million, or $0.11 per share, an improvement from a net loss of $28.5 million, or $0.20 per share, in Q1 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report due to improved net loss and significant reduction in R&D expenses, alongside progress in key clinical trials, though the company remains in a loss-making stage.

Positives

• Topline results for the Phase 2 SANRECO trial of divesiran are on track for August 2026.
• Abstracts for both divesiran (SANRECO Phase 1) and SLN312 (AZD1705 Phase 1) were accepted for presentations at major medical congresses (EHA and EAS, respectively).
• Collaboration revenue increased to $0.4 million in Q1 2026 from $0.1 million in Q1 2025.
• R&D expenses significantly decreased to $9.1 million in Q1 2026 from $20.8 million in Q1 2025.
• Net loss improved to $15.0 million in Q1 2026 from $28.5 million in Q1 2025.
• Loss per share improved to $0.11 in Q1 2026 from $0.20 in Q1 2025.

Negatives

• The company reported a net loss of $15.0 million for the first quarter of 2026.
• Cash, cash equivalents, and short-term investments decreased from $118.7 million at the end of 2025 to $102.9 million at the end of Q1 2026.
• The company has a history of net operating losses.

Risks

• The company's ability to obtain necessary capital to fund its clinical programs.
• The early stages of clinical development of the company's product candidates.
• The company's ability to obtain regulatory approval of and successfully commercialize its product candidates.
• Any undesirable side effects or other properties of the company's product candidates.
• The company's reliance on third-party suppliers and manufacturers.
• The outcomes of any future collaboration agreements.
• The company's ability to adequately maintain intellectual property rights for its product candidates.

Future Outlook

The company is focused on progressing divesiran towards topline results in the SANRECO Phase 2 trial in August 2026 and advancing its mRNAi GOLD platform. Forward-looking statements indicate potential therapeutic benefits and future results from ongoing trials.

Management Comments

• The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD platform, and we remain well positioned as we approach a significant company milestone.
• With Phase 2 topline results in PV expected this August, our team remains focused on progressing divesiran and delivering long-term value for patients and shareholders.

Industry Context

StockSavvy.ai notes that Silence Therapeutics is operating in the competitive and rapidly evolving field of RNA interference (RNAi) therapeutics. The company's focus on siRNA technology and specific disease targets like polycythemia vera and dyslipidemia aligns with broader industry trends towards precision medicine and genetic therapies. Progress in clinical trials and platform development are key value drivers in this sector.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if clinical trials are successful and product candidates gain regulatory approval. Improved net loss and reduced R&D spending may be viewed positively.
• Patients: Advancement of divesiran for polycythemia vera and SLN312 for dyslipidemia offers potential new treatment options.
• Employees: Continued progress in R&D and clinical development supports the company's mission and future prospects.

Next Steps

• Receive topline results from the SANRECO Phase 2 trial of divesiran in August 2026.
• Present Phase 1 study abstract for divesiran at the EHA 2026 Annual Congress (June 11-14, 2026).
• Present Phase 1 study abstract for SLN312 at the EAS Congress (May 24-27, 2026).

Key Dates

Recommendation

The company shows promising clinical development progress and improved financial metrics (reduced net loss and R&D spend), but remains in early-stage development with significant risks and a substantial cash burn. The upcoming topline results for the SANRECO trial are a key catalyst, making a 'hold' appropriate until more data is available.

Keywords

Silence Therapeutics, siRNA, Divesiran, Polycythemia Vera, SANRECO trial, SLN312, Biotechnology, Clinical Stage